By Fineline Cube 
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in the Phase III study of its investigational bispecific antibody drug conjugate (ADC), BL-B01D1. This milestone marks significant progress in the development of novel therapies for patients with locally advanced or metastatic urothelial carcinoma (UC) who have failed previous platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy.
Drug Mechanism
BL-B01D1 is a bispecific ADC targeting both EGFR and HER3, designed to deliver cytotoxic agents directly to cancer cells expressing these receptors. This dual targeting approach enhances the drug’s ability to bind to tumor cells and deliver therapeutic effects, making it a promising candidate for the treatment of UC.
Clinical Trial Progress
The Phase III study will evaluate the efficacy and safety of BL-B01D1 in patients with UC who have not responded to standard treatments. The trial aims to provide critical data supporting the drug’s potential to improve outcomes for patients with this aggressive form of cancer.-Fineline Info & Tech